Advertisement

Topics

Oncogenic BRAF in cancer - Biotech, Pharma and Life Science Channel

01:13 EST 24th January 2019 | BioPortfolio

Oncogenic BRAF can result from mutations in the BRAF gene, which may cause the protein to become overactive. The most common alteration in the BRAF gene leads to the BRAFV600E mutation. Mutations in the BRAF gene allow for BRAF to signal independently of upstream cues, and result in overactive downstream signaling via MEK and ERK. This, in turn, leads to excessive cell proliferation and survival, independent of growth factors.

Source: http://www.biooncology.com/research-education/braf/targeting

PubMed Articles [218 Associated PubMed Articles listed on BioPortfolio]

Mixed squamous cell and glandular papilloma of the lung: A case report of a novel mutation in the BRAF gene and coexistent HPV infection, possible relationship to ciliated muconodular papillary tumor.

Mixed squamous cell and glandular papilloma (mixed papilloma) is a very rare tumor, with fewer than 25 cases having been reported in the literature. Although a scattering of cases of p16 overexpressio...

KLF9-dependent ROS regulate melanoma progression in stage-specific manner.

Although antioxidants promote melanoma metastasis, the role of reactive oxygen species (ROS) in other stages of melanoma progression is controversial. Moreover, genes regulating ROS have not been func...

Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.

Attenuated Listeria monocytogenes (Lm-LLO) represents a valuable anticancer vaccine and drug delivery platform. Here we show that in vitro Lm-LLO causes ROS production and, in turn, apoptotic killing ...

Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.

Papillary thyroid carcinoma (PTC) is most common among all thyroid cancers. Multiple genomic alterations occur in PTC, and gene rearrangements are one of them. Here we screened 14 tumors for novel fus...

Impact of tumor-associated macrophages and BRAF mutation on clinical outcomes in patients with various thyroid cancers.

Tumor-associated macrophages (TAMs) play a role in thyroid cancer tumor progression and metastasis. This study aimed to investigate the association of TAM density and cluster of differentiation 68 (CD...

Clinical challenges in a patient with two BRAF V600E-mutated diseases.

Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia.

The combination of a BRAF inhibitor dabrafenib and a MEK inhibitor trametinib (CombiDT) has improved outcomes compared with chemotherapy or BRAF inhibitor monotherapy in advanced BRAF V600E/K melanoma...

B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.

Copy number gains, point mutations and epigenetic silencing events are increasingly observed in genes encoding elements of the Ras/Raf/MEK/ERK signaling axis in human breast cancer. The three Raf kina...

Targeted genomic profiling of acral melanoma.

Acral melanoma is a rare type of melanoma that affects world populations irrespective of skin color and has worse survival than other cutaneous melanomas. It has relatively few single nucleotide mutat...

Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

"Follicular variant" papillary thyroid carcinomas (FV-PTC) that do not histologically invade have a miniscule risk of metastasis, and thus been reclassified as a tumor of low malignant potential, the ...

News Articles [93 Associated News Articles listed on BioPortfolio]

GI cancers remain some of the toughest nuts to crack, great to see progress at ASCO #GI19 esp w biomarker-based strategy $MRK Keytruda in PD-L1+ 2L Esophageal: OS HR=.69 $MRK Keytruda+Herceptin+Chemo 87% ORR in HER2+ 1L mEGA $NVS Dabrafenib+Trametinib

GI cancers remain some of the toughest nuts to crack, great to see progress at ASCO #GI19 esp w biomarker-based strategy $MRK Keytruda in PD-L1+ 2L Esophageal: OS HR=.69 $MRK Keytruda+Herceptin+C...

NICE recommends Pierre Fabre's Braftovi in BRAF V600-mutated advanced melanoma http://bit.ly/2DmxCTy  #pharma #cancerpic.twitter.com/MMU8xrJf1j

NICE recommends Pierre Fabre's Braftovi in BRAF V600-mutated advanced melanoma http://bit.ly/2DmxCTy  #pharma #cancer pic.twitter.com/MMU8xrJf1j

NICE recommends Pierre Fabre's Braftovi in BRAF V600-mutated advanced melanoma

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by UK drug watchdog NICE for the treatment of unresectabl...

'Incredibly Impressive' Activity in Biliary Ca with Combo Tx

(MedPage Today) -- Responses in about 40% of patients with BRAF/MEK inhibitor pairing

BRAF, MEK Inhibitors Offer Promise in Biliary Tract Cancer

Researchers tested the combination of dabrafenib and trametinib in a phase II trial of patients with biliary tract cancer and BRAF V600E mutations.

Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma

Array Announces Updated Safety and Efficacy Results from the Phase 3 Trial Evaluating the Combination of Braftovi, Mektovi and Erbitux in Colorectal Cancer

BOULDER, Colo., Jan. 14, 2019 /PRNewswire/ — Array BioPharma Inc. (Nasdaq: ARRY) today announced updated safety and efficacy results, including mature overall survival (OS), ...

Pierre Fabre and its Partner Array BioPharma Announce 15.3 Months Median OS Observed from the Phase 3 BEACON CRC Safety Lead-in of BRAFTOVI, MEKTOVI and ERBITUX in BRAF-Mutant Metastatic CRC

- Data will be presented at ASCO 2019 Gastrointestinal Cancers Symposium - - Updated confirmed ORR remains 48% and updated median PFS remains 8.0 months - Intended for international media only/not...

Creative Diagnostics Introduces Pathology Antibodies for Researchers

Creative Diagnostics now is proud to announce that it launches a number of high quality pathology antibodies including Her2, PD-1, Ki-67, Tim3, CTLA4, Lp-PLA2, Muc2, Cytokeratin 18, BRAF V600E, IDH1 R...

$ARRY Announces 15.3 Months Median OS from the Safety Lead-in of the Ph 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer https://www.prnewswire.com/news-releases/array-biopharma-announce

$ARRY Announces 15.3 Months Median OS from the Safety Lead-in of the Ph 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer ...

Companies [1 Associated Companies listed on BioPortfolio]

NewGene Limited

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genet...

Clinical Trials [140 Associated Clinical Trials listed on BioPortfolio]

Preclinical Validation of New Anti-melanoma Compounds

This research program is in keeping with the chemistry/biology/clinical interface and gathers 4 teams with complementary expertise in these respective fields. It will allow deciphering the...

Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib an...

Anlotinib Combined With Pemetrexed And Carboplatin as the First-line Treatment in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer

In recent years, with the progress in the treatment field, Non-Small Cell Lung Cancer(NSCLC) has become the most successful cancer species in precision medicine. Patients with positive dri...

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

This is a phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by HL-085 plus V...

Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC

In recent years, with the progress in the treatment field, NSCLC has become the most successful cancer species in precision medicine. Patients with positive driving genes such as EGFR, ALK...

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

This phase 1/2 trial addresses the efficacy and safety of the combination of dabrafenib, trametinib and the oral autophagy inhibitor hydroxychloroquine in patients with unresectable AJCC (...

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

This is an open label, single-arm, phase IB treatment study to determine the safety of administering anti-PD1 monoclonal antibodies with AV-MEL-1 and to get some suggestion of efficacy, in...

Myeloma-Developing Regimens Using Genomics (MyDRUG)

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead t...

FIVC in Advanced Colorectal Cancer Patients With BRAF V600E Mutation.

This clinical trial aims to evaluate the efficacy, safety of FOLFIRI with vemurafenib and cetuximab in Advanced Colorectal Cancer Patients with BRAF V600E mutation.

Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

Lung cancer is diagnosed at metastatic stage in 60% of the cases. For these patients, first-line treatment is based on histology and molecular characterization of non-squamous non-small ce...

Medical and Biotech [MESH] Definitions

None available.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...